The settlement of this shareholder class action lawsuit is on behalf of investors who held CM Life Sciences III, Inc. (“CM Life Sciences”) (NASDAQ: CMLT) common stock immediately following the Redemption Deadline of 5:00 PM ET on December 14, 2021 (the “Redemption Deadline”), either of record or beneficially.
CM Life Sciences agreed to pay $7,250,000 to resolve this class action lawsuit alleging the company and certain of its officers and/or directors breached their fiduciary duties to the Class.
What’s the status of the Settlement?
On January 23, 2026, the Court granted Preliminary Approval of the Class Action Settlement. There is a Final Settlement Hearing scheduled for April 21, 2026. The settlement website is active and open for claims.
Who can file a claim?
The settlement class includes all persons or entities who:
- Held CM Life Sciences common stock immediately following the Redemption Deadline on December 14, 2021.
How much is the Settlement Payment?
Pro rata payment: The total settlement fund is $7,250,000. The amount each class member receives will depend on several factors, including:
- The number of valid claims submitted
- The number of shares purchased and sold
- The dates of purchase and sale
- The price paid for the shares and the price received upon sale
How do I file a claim?
The deadline to file a claim is May 25, 2026. To submit a claim and/or to find additional information regarding the terms of the settlement and claim filing process, go to www.cmlsiiistockholdersettlement.com, or contact the claims administrator, JND Legal Administration at 1-877-206-2312.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.